Drug Trial Radar · NCT07227012
Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.
Last checked: Nov 20, 2026Latest source record: Oct 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
138
Planned (sponsor's estimate)
Start
Dec 1, 2025
Primary completion
Oct 18, 2027
Study completion Oct 17, 2028
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Nov 12, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to learn about the effects of study medicine (PF-08634404) when given alone or with another antibody (ipilimumab) for the treatment of a type of liver cancer called hepatocellular carcinoma (HCC) that is either locally advanced (spread to nearby tissues) or has spread to other parts of the body. To join the study, participants must meet the following conditions: * Be 18 years or older. * Have locally advanced or metastatic HCC. * Is not a candidate for complete surgical or loco-regional therapies. * Have not received any whole-body treatment for HCC. Participants will receive PF-08634404 either alone or in combination with ipilimumab. The medicine will be given through intravenous (IV) infusions, which means it will be administered directly into a vein. All treatments will take place at clinical trial sites, where trained medical staff will monitor participants during and after each visit.
Conditions
- Carcinoma, Hepatocellular
- Hepatocellular Cancer
- Hepatocellular Carcinoma
- Unresectable Hepatocellular Carcinoma
- Liver Neoplasms
- Advanced Hepatocellular Carcinoma
- Metastatic Hepatocellular Carcinoma
Interventions
PF-08634404Biological
Solution for infusion
IpilimumabBiological
Solution for infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Adverse EventsTime frame: Through end of study and up to approximately 24 months
- Phase 1b: Number of participants with Dose limiting toxicities (DLT)Time frame: Through 90 days after the last dose of study intervention; Approximately 24 months
- Phase 2: Confirmed Overall Response Rate (ORR) using RECIST 1.1 as assessed by investigatorTime frame: Approximately 24 months
- Phase 2: Recommended dose of PF-08634404 in combination with ipilimumabTime frame: Approximately 24 months
Locations
60 sites in 5 countries. Site status is shown where the registry gives one.
Chao Family Comprehensive Cancer Center and Ambulatory Care
Irvine, California · Recruiting
UCI Health - Irvine Infusion Pharmacy ACC
Irvine, California · Recruiting
UCI Health - Irvine
Irvine, California · Recruiting
START Los Angeles, LLC
Los Angeles, California · Recruiting
Keck Hospital of USC
Los Angeles, California · Recruiting
Los Angeles General Medical Center
Los Angeles, California · Recruiting
USC/Norris Comprehensive Cancer Center / Investigational Drug Services
Los Angeles, California · Recruiting
USC/Norris Comprehensive Cancer Center
Los Angeles, California · Recruiting
LACN Century City
Los Angeles, California · Recruiting
UC Irvine Health - Chao Family Comprehensive Cancer Center
Orange, California · Recruiting
Keck Medical Center of USC Pasadena
Pasadena, California · Recruiting
Moffitt Cancer Center at Speros
Land O' Lakes, Florida · Recruiting
Moffitt Cancer Center at SouthShore
Ruskin, Florida · Recruiting
Moffitt Cancer Center - International Plaza
Tampa, Florida · Recruiting
Moffitt Cancer Center - McKinley Campus
Tampa, Florida · Recruiting
Moffitt Cancer Center
Tampa, Florida · Recruiting
Moffitt McKinley Hospital
Tampa, Florida · Recruiting
Moffitt Cancer Center at Wesley Chapel
Wesley Chapel, Florida · Recruiting
Memorial Hospital
Shiloh, Illinois · Recruiting
Siteman Cancer Center - Shiloh
Shiloh, Illinois · Recruiting
Allina Health Cancer Institute - Mercy Hospital
Coon Rapids, Minnesota · Recruiting
Allina Health Cancer Institute - Abbott Northwestern Hospital
Minneapolis, Minnesota · Recruiting
Allina Health Cancer Institute - United Hospital
Saint Paul, Minnesota · Recruiting
Siteman Cancer Center - St. Peters
City of Saint Peters, Missouri · Recruiting
Siteman Cancer Center - West County
Creve Coeur, Missouri · Recruiting
Siteman Cancer Center - North County
Florissant, Missouri · Recruiting
Saint Luke's Cancer Institute
Kansas City, Missouri · Recruiting
Saint Luke's Hospital of Kansas City
Kansas City, Missouri · Recruiting
Siteman Cancer Center
St Louis, Missouri · Recruiting
Barnes-Jewish Hospital
St Louis, Missouri · Recruiting
Washington University School of Medicine - Siteman Cancer Center
St Louis, Missouri · Recruiting
Siteman Cancer Center - South County
St Louis, Missouri · Recruiting
Renown Health Medical Oncology
Reno, Nevada · Recruiting
Renown Office of Clinical Research
Reno, Nevada · Recruiting
Renown Regional Medical Center
Reno, Nevada · Recruiting
Duke Cancer Center Cary
Cary, North Carolina · Recruiting
Duke Cancer Center - Investigational Chemotherapy Service
Durham, North Carolina · Recruiting
Duke Cancer Center
Durham, North Carolina · Recruiting
Duke University - Main Hospital and Clinics
Durham, North Carolina · Recruiting
Duke Cancer Center Raleigh
Raleigh, North Carolina · Recruiting
Showing 40 of 60 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.